Assetmark Inc. Decreases Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Assetmark Inc. trimmed its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 96.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,323 shares of the medical device company's stock after selling 38,408 shares during the period. Assetmark Inc.'s holdings in DexCom were worth $103,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Covestor Ltd boosted its stake in DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company's stock worth $64,000 after purchasing an additional 335 shares during the period. Harbour Investments Inc. boosted its stake in DexCom by 8.8% during the 3rd quarter. Harbour Investments Inc. now owns 12,895 shares of the medical device company's stock worth $864,000 after purchasing an additional 1,046 shares during the period. GSA Capital Partners LLP boosted its stake in DexCom by 129.1% during the 3rd quarter. GSA Capital Partners LLP now owns 10,268 shares of the medical device company's stock worth $688,000 after purchasing an additional 5,787 shares during the period. OVERSEA CHINESE BANKING Corp Ltd acquired a new stake in DexCom during the 3rd quarter worth $221,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in DexCom by 6.2% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 949,565 shares of the medical device company's stock worth $63,659,000 after purchasing an additional 55,542 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DXCM has been the topic of several analyst reports. Robert W. Baird raised shares of DexCom from a "neutral" rating to an "outperform" rating and lifted their target price for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and lifted their target price for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Finally, Citigroup boosted their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, DexCom currently has a consensus rating of "Moderate Buy" and an average target price of $99.82.

Remove Ads

DexCom Trading Down 0.9 %

DXCM stock traded down $0.65 on Tuesday, hitting $70.70. 2,603,968 shares of the company were exchanged, compared to its average volume of 3,881,061. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The business's fifty day moving average is $83.82 and its two-hundred day moving average is $76.94. The stock has a market capitalization of $27.63 billion, a price-to-earnings ratio of 49.44, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insiders Place Their Bets

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the business's stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the business's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 104,657 shares of company stock worth $8,019,422 over the last ninety days. 0.30% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.